top of page

London's Epsilogen completed a £12.5 million Series B expansion this week to take its IgE based folate receptor alpha program into a phase 1b study

  • Sep 12, 2024
  • 1 min read

CEO Tim Wilson describes the rationale for focusing on IgE, and why the company has chosen folate receptor alpha as its first target. This new fundraising brings total series B funds raised to £43.25 million.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

10x_Genomics_logo.svg.png

10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health. Cited in more than 10,000 research papers, our innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more.

 

Our talented, dedicated science professionals have a distinguished record of creating innovative instruments, reagents, and software that analyze biological systems at a resolution that matches the complexity of biology.

bottom of page